http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2448694-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b17693654a51f9ab41267dfe1465621 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-15 |
| filingDate | 2007-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_733ba2ae946a0bc1b6ed566722325b05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ecc19045f3ac02ff87568a9e4fceef3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d4925bfb1cea7e380c0f7665f80ea1f |
| publicationDate | 2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2448694-C2 |
| titleOfInvention | Method for counteracting formation of neurotoxic proteins addl (versions), method for modulating neuronal dysfunction or neurotoxicity by means of non-peptide compound and based composition (versions) |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: group of inventions refers to medical chemistry and concerns using non-peptide compounds for inhibiting the oligomerisarion of monomer peptides Aβ 1-42 . There are offered methods for counteracting formation of neurotoxic proteins ADDL from monomer peptides Aβ 1-42 , as well as methods for suppressing, regulating and/or modulating neuronal dysfunction or neurotoxicity caused by the proteins ADDL in nerve cells or nerve tissue due to suppressing formation of the proteins ADDL, involving the contact of monomer Aβ 1-42 and a compound specified in a group consisting of: (Z)-N-(2-Methoxy-phenyl)-2-oxo-2-{N'-[3-oxo-3-thiophen-2-yl-1-trifluoromethyl-propylidene]-hydrazino}-acetamide, ethyl ether of (E)-2-{[1-(2-hydroxy-3-methoxy-phenyl)-methylidene-hydrazinooxalyl]-amino}-6-metyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid, ethyl ether of (E)-2-{[1-(2-hydroxynaphthalen-1-yl)-methylidene-hydrazinooxalyl]-amino}-6-metyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid, ethyl ether of (E)-2-{[1-(2-hydroxyphenyl)-methylidene-hydrazinooxalyl]-amino}-6-metyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid, 2-(5-Hydroxy-3-isobutyl-5-(triflouromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide and (E)-2-Hydroxy-N'-((1-hydroxynaphthalen-2-yl)mehtylene)banzohydrazide. There are also presented compositions containing an effective amount of the compounds stated above. n EFFECT: group of invention provides the candidate compounds for developing drug preparations for neurodegenerative disorders associated with the proteins ADDL, particularly Alzheimer's disease. n 25 cl, 2 dwg, 1 tbl, 3 ex |
| priorityDate | 2007-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 111.